BNS, 19.05.2026.
The results of the European Federation of Pharmaceutical Industries and Associations (EFPIA) Patients W.A.I.T. 2025 survey show that patient access to innovative medicines remains highly uneven across Europe. In Estonia, availability is affected by the peculiarities of a small market, a limited healthcare budget, and a lengthy assessment process.
The results of the European Federation of Pharmaceutical Industries and Associations (EFPIA) Patients W.A.I.T. 2025 survey show that patient access to innovative medicines remains highly uneven across Europe. In Estonia, availability is affected by the peculiarities of a small market, a limited healthcare budget, and a lengthy assessment process.
Pieteikšanās reģistrētiem LPMA biedriem.